Ann: Quarterly Activities Report and Appendix 4C, page-244

Beyond ResAppDx and SleepCheck, we announced a nonexclusive licensing deal with AstraZeneca Japan during the quarter. This is a major achievement and highlights the potential use of our technology with some of the world's most renowned companies. AstraZeneca will be using a new app, which we've built that counts patients coughs over extended periods and is able to accurately differentiate coughs from background noise. AstraZeneca will use the app in a clinical study of cancer patients, allowing study investigators to remotely monitor patients' respiratory health in real time. We've been working closely with AstraZeneca to localize and refine the app to their specification and is currently undergoing testing by the AstraZeneca team. Once the 2-year study begins, we'll receive a monthly license fee for each patient enrolled as well as a monthly support fee. While not expected to deliver significant revenue, the progress has certainly opened the door for us with AstraZeneca and allowed us to progress discussions with them on additional collaborations. There's also progress -- conversations with other parties interested in this technology. The need for long-term monitoring of patients in clinical trials or monitoring patients with chronic disease is an important emerging opportunity for ResApp. And the initial work with ResApp's had with AstraZeneca, that's an important base.